ProShares Ultra Nasdaq Biotechnology (BIB)
81.05
-0.11
(-0.13%)
USD |
NASDAQ |
Dec 08, 14:26
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.95% | 0.01% | 86.02M | 19693.20 |
| Weighted Average Dividend Yield | Turnover Ratio (Generic) | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.72% | 28.00% | -11.88M | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to two times the return of the Nasdaq Biotechnology Index. The Index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProShares |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 08, 2025.
Asset Allocation
As of October 31, 2025.
| Type | % Net |
|---|---|
| Cash | 20.11% |
| Stock | 63.63% |
| Bond | 7.20% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 9.06% |
Basic Info
| Investment Strategy | |
| The Fund seeks daily investment results, before fees and expenses, that correspond to two times the return of the Nasdaq Biotechnology Index. The Index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Miscellaneous |
| Broad Category | Equity |
| Global Peer Group | Alternative Equity Leveraged |
| Peer Group | Equity Leverage Funds |
| Global Macro | Alternative Equity |
| US Macro | Large-Cap Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Equity Leverage Funds |
| Fund Owner Firm Name | ProShares |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |